The post-cycle window is the most under-tracked part of every peptide protocol. The user finishes the cycle, the supply runs out or the washout starts, and the daily log usually stops at the same time. This is exactly backwards. The post-cycle window is when the protocol’s actual effects show up - the outcome trend, the rebound patterns, the durability of what changed during the cycle - and the data accumulated here is what determines whether to repeat the cycle, modify it, or stop. This guide is the operational tracking protocol for the 4 to 8 weeks after the last injection.
Why the post-cycle window matters
Most peptide protocols are not a single isolated cycle. Most users run multiple cycles, sometimes years apart, sometimes back-to-back with washouts. The decision about the next cycle - whether to run it, when, at what dose, in what stack - depends almost entirely on what the post-cycle data shows.
Three reasons the post-cycle data is the most valuable data the protocol generates. First, in-cycle improvements are confounded by the active compound. Whether a sleep score is good because of the compound, the placebo effect, or other lifestyle changes is impossible to disentangle while the compound is active. Post-cycle, the compound is no longer the variable. Second, durable benefits versus transient benefits separate cleanly post-cycle. The thing that improved and stayed improved at week 4 post-cycle is the structural change; the thing that improved and reverted is the compound-dependent change. Third, the next cycle decision becomes a structured comparison. Without post-cycle data, the decision is ‘I think it helped’ versus ‘I think it did not.’ With post-cycle data, the decision is ‘sleep was 23% better in-cycle, stayed 12% better at week 4 post, reverted to baseline at week 8.‘
What to track in the first 4 weeks post-cycle
The first 4 weeks after the last injection are the most important post-cycle tracking window. Continue:
- Daily six-dimension symptom rubric. Energy, drive, libido, irritability, social motivation, anhedonia, on a 1-to-5 scale. The same rubric that ran in-cycle.
- Indication-specific outcome. Whatever the cycle was running for. For a GLP-1 cycle, weight and appetite. For a BPC cycle, pain or function in the indicated area. For a growth-hormone-axis cycle, sleep and recovery scores. Daily 1-to-5.
- Sleep quality and architecture. Especially relevant for any cycle that included growth-hormone-axis peptides. Track deep sleep minutes from wearable; subjective sleep score 1-5.
- Resting heart rate. Useful for any cycle but especially for retatrutide or other cardiometabolic-active compounds.
- Hydration and protein. Continue tracking these; they remain the operational levers for body composition.
- Wearable summary. HRV, recovery score, and any other wearable metrics that ran in-cycle.
Thirty seconds per evening, same as in-cycle. The structural similarity is the point - the comparison data only works if the tracking instrument is the same.
What rebound looks like by compound class
Rebound effects post-cycle vary by compound class. Worth knowing the typical patterns so the log captures the right signals.
GLP-1s (semaglutide, tirzepatide, retatrutide). The appetite rebound is the most predictable post-cycle effect. Within 2-4 weeks of the last injection, appetite typically returns to or near pre-protocol baseline. The food-noise that was absent during the cycle returns. Body weight regain in the absence of changed habits is the well-documented outcome in the discontinuation arms of the major trials. The tracking value is the rate of rebound - whether the appetite returns gradually or quickly, and whether the protein-and-training habits established during the cycle persist or fade.
Growth-hormone-axis peptides (CJC-1295, ipamorelin, sermorelin). Sleep architecture shifts post-cycle. Some users report vivid dreams subsiding within 2 weeks; some report a slight rebound dip in deep sleep before returning to pre-protocol baseline. IGF-1 typically falls back toward baseline over 4-8 weeks.
BPC-157. The indication-specific outcome typically holds or slowly fades depending on what the cycle was running for. Soft-tissue injury cycles often show durable improvement if the cycle ran long enough to allow tissue remodeling. Recovery support cycles often see the improvement fade gradually.
Healing peptide stacks (BPC + TB-500). Similar to BPC alone, with the caveat that long-cycle stacks tend to produce more durable effects than short cycles.
The post-cycle log captures whichever pattern is relevant for the compound class.
Re-baselining at week 4 post-cycle
Week 4 post-cycle is the re-baseline point. At this point, the acute effects of the compound have washed out, the structural changes have settled, and the values you log are a reasonable estimate of your post-protocol baseline.
The week-4 re-baseline should include:
- Symptom rubric baseline. The 7-day average of the six-dimension scores in week 4 post-cycle. Lock as the new baseline.
- Indication outcome baseline. The 7-day average of whatever the indication-specific outcome was. Lock as new baseline.
- Smoothed weight (for GLP-1 cycles). The 14-day moving average at week 4 post-cycle.
- Sleep and recovery baseline. 7-day averages from wearable.
- Resting HR baseline. Daily morning averages over the week.
- Quarterly lab panel if timing aligns. The first lab panel post-cycle becomes the comparison for in-cycle panels.
This re-baseline is the comparison data for any future protocol. If you start a next cycle 6 months later, the week-4 post-cycle baseline is what the in-cycle data is compared against. Without it, every cycle is its own isolated data island.
What miora does through the post-cycle window
The post-cycle workflow in miora is straightforward and starts before the cycle ends.
Last week of cycle. miora’s daily check continues unchanged. The weekly summary notes that the post-cycle window is approaching and the daily log will continue.
Day after last injection. The evening text changes slightly - ‘post-cycle day 1: same rubric, same outcome metric.’ miora explicitly notes the cycle has ended and the post-cycle tracking has started.
Weeks 1-4 post-cycle. Daily check continues. Weekly summary surfaces the indication-outcome trend, the rebound pattern relative to typical for the compound class, and any flags.
Week 4 re-baseline. miora explicitly locks the new baseline values and confirms the comparison data for any future cycle.
Weeks 5-8 post-cycle. Daily check can drop to weekly summary cadence if the rebound has stabilized. Some users prefer to keep daily logging running indefinitely; the data is useful and the burden is minimal.
If the next cycle is being planned, the post-cycle data feeds directly into the clinician conversation about whether to run, what to modify, and what stacking changes to consider.
How post-cycle data changes the next cycle decision
The structured post-cycle data turns the next-cycle decision from a guess into a comparison. Several scenarios:
The cycle produced durable improvement. Outcome metric improved during cycle, stayed improved at week 4 post-cycle, partially or fully maintained at week 8. The next cycle question is whether to maintain or modify. The data supports a shorter or lower-dose next cycle in many cases.
The cycle produced transient improvement. Outcome improved during cycle, reverted to baseline by week 4 post-cycle. The next cycle question is whether the compound was actually working or whether the improvement was placebo or coincidence. Re-running the same cycle is the obvious next step but may not produce a different outcome.
The cycle produced rebound worse than baseline. Outcome reverted to worse than pre-cycle baseline. This is a flag worth taking to a clinician. Rebound-worse-than-baseline can indicate dependency-like adaptation or that the compound was suppressing an underlying issue that resurfaced.
The cycle produced no measurable change. No improvement in cycle, no change post-cycle. The protocol was not doing what it was supposed to. The next decision is whether to change the dose, the compound, the stack, or stop.
Each of these is a different conversation and a different decision. The post-cycle data is what enables the decision to be structured rather than guessed.
When to flag the post-cycle trend
Specific thresholds worth bringing to a clinician during the post-cycle window:
- Mood drift across 2 weeks post-cycle. The post-cycle period can surface mood changes that were masked during the cycle. The six-dimension mood rubric applies.
- Outcome metric worse than pre-cycle baseline at week 4 post. Rebound-worse-than-baseline; worth investigating.
- Resting HR not returning toward baseline. Cardiometabolic-active compounds should show HR return within 4-6 weeks; if not, worth labs.
- Weight regain on GLP-1 cycle faster than 1.5% body weight per month. Aggressive regain often indicates that the protein-and-training habits did not persist. The intervention is behavioral, not pharmacological.
- Sleep architecture not normalizing post-cycle for growth-hormone-axis peptides. Worth a sleep study consultation if persistent.
- New symptoms emerging post-cycle. Unusual but worth flagging.
The clinician conversation about whether to run a next cycle benefits from the four-week post-cycle chart more than from any other single data set.
What this guide does not do
Two boundaries.
This guide does not recommend continuing or discontinuing any specific peptide protocol. The decision to end a cycle, run a next cycle, or modify the approach belongs with your clinician.
This guide does not interpret post-cycle data clinically. miora surfaces patterns and trends; the clinical interpretation - whether a specific rebound is significant, whether a specific lab trend warrants action - belongs with your prescriber. This content is for informational purposes only and is not medical advice. Peptide and GLP-1 protocols require clinician supervision throughout the cycle and post-cycle window.
